Our findings that EC‐linked mutations in FGFR2 increase ADAM17 activity provides a well‐defined description of a molecular mechanism associated with these pathogenic mutations, implicates increased ADAM17 activity in tumour formation and identifies a new druggable target in EC. This evidence concerns the gene FGFR2 and neoplasm.